Advances in genetic testing have increased awareness of inherited mutations linked to cancer risk, particularly those involving the BRCA1 and BRCA2 genes. These genes, which play a critical role in DNA repair, have been associated with a predisposition to several cancer types, including breast, ovarian, pancreatic, and prostate cancers. Though carrying mutations in BRCA1 or BRCA2 raises the likelihood of developing cancer, experts emphasize that these mutations indicate susceptibility rather than certainty. Some individuals with BRCA mutations may never develop cancer, while others, especially women, face a significantly elevated risk.

BRCA1 and BRCA2 mutations differ in their associated cancer risks and typical age of onset. For example, a recent study indicated that women with a BRCA1 mutation have a 56.8 percent chance of developing ovarian cancer between ages 30 and 80, compared with a 25.4 percent chance for those with BRCA2 mutations. Cancers associated with BRCA1 tend to be diagnosed at younger ages. Both genes are strongly linked to breast and ovarian cancers in women, as well as prostate and pancreatic cancers, with BRCA2 mutations showing a more established connection to the latter two.

Genetic counselors and oncologists highlight the importance of personalized risk assessments, which take into account family history, lifestyle, and the specific genetic variant involved. These factors collectively influence an individual’s cancer risk and guide decisions about screening and preventive measures. Current guidelines recommend genetic testing for individuals diagnosed with certain cancers—such as pancreatic, ovarian, aggressive prostate, or early-onset breast cancer—as well as for those with a family history suggestive of hereditary cancer syndromes.

Cascade testing, in which family members of someone with a known mutation undergo genetic testing, is a common approach to identifying carriers. For instance, influencer Alix Earle and her sister, Ashtin, both tested positive for a BRCA2 mutation after their mother was diagnosed with breast cancer and found to carry the mutation. If a first-degree relative tests positive, subsequent testing often extends to their immediate family members to identify others at risk.

While a personal cancer history or known familial mutation significantly prompts testing, experts caution that current guidelines may overlook many carriers. Research indicates disparities in access to and uptake of genetic testing, with certain populations—such as those of Ashkenazi Jewish descent, where about 1 in 40 individuals carry specific BRCA mutations—being encouraged to consider testing even without a cancer diagnosis or family history. However, other groups, including Asian, Black, and Hispanic populations, have been less likely to receive genetic testing after a cancer diagnosis, highlighting ongoing challenges in equitable healthcare access.

Genetic testing can have implications beyond prevention, potentially influencing cancer treatment strategies, and is often covered by health insurance. Experts recommend consulting with genetic counselors to interpret family histories and determine the appropriateness of genetic testing. As research continues, medical professionals are refining risk assessments and screening recommendations to better support individuals with BRCA mutations and their families.